US Pharm. 2010;35(10):HS-32.
Researchers from the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were instrumental in a study that led to the FDA's recent fast tracking of ipilimumab, a treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010, the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.
